Herold Advisors Inc. Buys 1,026 Shares of Pfizer Inc. (NYSE:PFE)

Herold Advisors Inc. boosted its stake in Pfizer Inc. (NYSE:PFE) by 1.6% in the 4th quarter, Holdings Channel reports. The firm owned 63,762 shares of the biopharmaceutical company’s stock after acquiring an additional 1,026 shares during the quarter. Herold Advisors Inc.’s holdings in Pfizer were worth $1,836,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Atwater Malick LLC boosted its position in shares of Pfizer by 1.2% during the 3rd quarter. Atwater Malick LLC now owns 165,839 shares of the biopharmaceutical company’s stock valued at $5,501,000 after acquiring an additional 1,964 shares during the last quarter. Newbridge Financial Services Group Inc. raised its holdings in shares of Pfizer by 21.2% during the 3rd quarter. Newbridge Financial Services Group Inc. now owns 14,506 shares of the biopharmaceutical company’s stock valued at $481,000 after buying an additional 2,534 shares in the last quarter. Willis Investment Counsel raised its holdings in shares of Pfizer by 4.6% during the 3rd quarter. Willis Investment Counsel now owns 1,070,451 shares of the biopharmaceutical company’s stock valued at $35,507,000 after buying an additional 47,517 shares in the last quarter. Berkshire Money Management Inc. raised its holdings in shares of Pfizer by 3.5% during the 3rd quarter. Berkshire Money Management Inc. now owns 22,263 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 750 shares in the last quarter. Finally, Farmers & Merchants Trust Co of Chambersburg PA raised its holdings in shares of Pfizer by 3.5% during the 3rd quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 34,283 shares of the biopharmaceutical company’s stock valued at $1,137,000 after buying an additional 1,165 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

PFE opened at $25.40 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37. The stock has a market capitalization of $143.83 billion, a PE ratio of 70.50, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61. The stock’s 50 day moving average price is $26.96 and its 200-day moving average price is $28.42.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same period in the previous year, the firm earned $1.14 earnings per share. The business’s revenue was down 41.3% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.61%. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on PFE. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.